Daniela Shveid Gerson

MD, MSc 💜 Clinical oncology. Translational research, building patient relations 👥. Students are the best teachers.

[Daniela Shveid Gerson @DSG_MD]

@YJanjigianMD @MSKCancerCenter @Sam_Cytryn @AndreaCercek @EileenMOReilly @GABOUALFA @HardingJJMD Congratulations!!!! Undoubtedly a wonderful mentor ❣️☺️

[Daniela Shveid Gerson @DSG_MD]

@YJanjigianMD @oncodaily @ConquerCancerFd @MSK_DeptOfMed @MSKCancerCenter Congratulations!!!

[Daniela Shveid Gerson @DSG_MD]

@IlanaSchlam @stolaney1 @nlinmd Congrats!!! 🍾🎈🎊

[Daniela Shveid Gerson @DSG_MD]

@YJanjigianMD @NEJM @KoheiShitara @MSKCancerCenter Congratulations!!!

[Andrés Bonilla @linfoblastosabs]

In a joint work between hematology and oncology we present this narrative review

Thank you
@mistralCM @taliawegman @DSG_MD @trejo_becer

Somatic Landscape of Oncogenic Variants Across the Main Cancer Subtypes in Latin America: https://t.co/vOQ4Cx5e6J

[Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽 @Rfonsi1]

In ongoing care, clinical documentation, the most important part is to be told what the author is thinking. what is available elsewhere or the historic aspect is of much lower relevance.

[Daniela Shveid Gerson @DSG_MD]

@DianeReidyLagun @dukemedicine @DukeHealth @MSKCancerCenter Congratulations!!! 🎊🎈🎉

[JCO Global Oncology @JCOGO_ASCO]

Awareness, Knowledge & Treatment Patterns of Non-Metastatic Inflammatory #breastcancer in Low & Middle-Income Countries: The BRIDGES Study ➡️ https://t.co/q0Slu49aG2

Co-authors: @stolaney1 @curijoey @jenniferbellon2 @DSG_MD @inas_md @SarahSewar @jamecancerdoc @DFCI_BreastOnc

[Ilana Schlam @IlanaSchlam]

https://t.co/DYEZx1unxN

Grateful for amazing global 🌎collaborators that made this possible: @darioT_ @FilipaLynce @stolaney1 @curijoey @DSG_MD @inas_md @SarahSewar @jamecancerdoc @EnriqueSoto8 @Otto_DFCI @DFCI_BreastOnc @IBC_DanaFarber @OncoAlert

[Ilana Schlam @IlanaSchlam]

The BRIDGES study is now @JCOGO_ASCO

❓ Management of IBC in low and middle income countries
✅ 112 responses from clinicians from 36 counties
🔑 1/3 of patients with non metastatic IBC are receiving TMT
🔑 provider education everywhere is key to improve patient outcomes

[Daniela Shveid Gerson @DSG_MD]

@IlanaSchlam @DFCI_BreastOnc @stolaney1 @FilipaLynce @drsarahsam @PTarantinoMD @DrRFreedman @DanaFarber Congrats!!!🎈🎉🍾

[Ilana Schlam @IlanaSchlam]

Thank you @DSG_MD for inviting me to give grand rounds at the Centro Médico ABC in Mexico City ⭐️

[Daniela Shveid Gerson @DSG_MD]

@IlanaSchlam 🔝 as always!!!

[Ilana Schlam @IlanaSchlam]

Updated (non-exhaustive) breast cancer treatment algorithms, now including adjuvant ribociclib and other recent updates.

I am happy to be running out of space as treatment options continue to expand!

@OncoAlert #bcsm

[AMSA @AMSAMEXICO]

Mucha participación en el Seminario OMI-MEX CHOP de Liderazgo Médico 2024

#seminario #seminarios #medicina #medicos #médico #médicos #salud #health

[Charles Swanton @CharlesSwanton]

Why do some patients benefit less than others from precision cancer medicine? We are excited to share our paper "Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling” out in @NatureComms. https://t.co/e5AYdyrnbx 🧵

[Daniela Shveid Gerson @DSG_MD]

@dralanreyesonco Of course!
Check out @e_ESO at https://t.co/IS9lYr0DkS

[Daniela Shveid Gerson @DSG_MD]

@Daniela_Molena @YJanjigianMD Congrats!!!

[José Máximo Barros, MD 🇦🇷 @barrosonco]

@ESOncology
#ESOambassador
#meeting #workingGroup
@DSG_MD @Gordana5kovska @JoanaMarinhOnc @AnnaVasileva @anjakova
@fedrophd